0001415889-24-010138.txt : 20240403 0001415889-24-010138.hdr.sgml : 20240403 20240403180020 ACCESSION NUMBER: 0001415889-24-010138 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NOYES TIMOTHY P CENTRAL INDEX KEY: 0001185035 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 24820532 MAIL ADDRESS: STREET 1: 1365 MAIN STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-04032024_060408.xml X0508 4 2024-04-01 0001798749 Aerovate Therapeutics, Inc. AVTE 0001185035 NOYES TIMOTHY P C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 true true false false CHIEF EXECUTIVE OFFICER 1 Common Stock 2024-04-01 4 M 0 10000 2.14 A 10000 D Common Stock 2024-04-01 4 S 0 4502 28.9647 D 5498 D Common Stock 2024-04-01 4 S 0 1647 29.8955 D 3851 D Common Stock 2024-04-01 4 S 0 2851 31.0228 D 1000 D Common Stock 2024-04-01 4 S 0 1000 31.95 D 0 D Stock Option (Right to Buy) 2.14 2024-04-01 4 M 0 10000 0 D 2031-04-01 Common Stock 10000 373381 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.57 to $29.48, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.705 to $30.45, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.73 to $31.46, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. /s/ George A. Eldridge, Attorney-in-Fact 2024-04-03